Stay updated on DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial
Sign up to get notified when there's something new on the DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial page.

Latest updates to the DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check9 days agoChange DetectedDifference0.2%
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check38 days agoChange DetectedThe page has been updated to reflect a new version of the study protocol (v2.15.0) and includes the addition of collaborators, while significant details about the study's methodology and eligibility criteria have been removed.SummaryDifference51%
- Check46 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check53 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
Stay in the know with updates to DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial page.